Childhood Kidney Diseases

Korean Society of Pediatric Nephrology (대한소아신장학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical Outcomes of Non-carbapenem Treatment for Urinary Tract Infections Caused by Extended-spectrum β-lactamase-producing Escherichia coli

  • Kim, Eunae (Department of Pediatrics, Hallym University Kangnam Sacred Heart Hospital) ;
  • Ahn, Yo Han (Department of Pediatrics, Seoul National University Children's hospital) ;
  • Lee, Jung Won (Department of Pediatrics, Ewha Womans University School of Medicine) ;
  • Park, Eujin (Department of Pediatrics, Hallym University Kangnam Sacred Heart Hospital)
  • Received : 2021.04.20
  • Accepted : 2021.06.07
  • Published : 2021.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The purpose of this study was to investigate the clinical outcomes of non-carbapenem treatment for urinary tract infections (UTIs) caused by extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (E. coli) in young children. Methods: We retrospectively reviewed the medical records of children under 2 years of age who were diagnosed and treated for UTIs caused by ESBL-producing E. coli from September 2014 to March 2020. Results: Forty-three children under 2 years of age were treated with non-carbapenem antimicrobials for UTIs caused by ESBL-producing E. coli without bloodstream infections. The overall clinical and microbiological success rates for empirical antimicrobial treatment were 90.7% and 97.7%. Three of the patients (7.0%) experienced a relapse of UTI within a month. An in vitro susceptibility test showed that two patients were sensitive and one was resistant to the antimicrobial treatments. Furthermore, there were no significant differences in the time to defervescence, clinical success, microbiological success, and relapse rate between the susceptible (n=13) and non-susceptible groups (n=30). Conclusion: In this study, the overall relapse rate of patients treated with non-carbapenem antimicrobials was 7.0%. The patients showed high success rates in the clinical and microbiological responses to the non-carbapenems regardless of the results of the in vitro antimicrobial susceptibility test. These results provide evidence that non-carbapenems may be viable alternative treatments for UTIs caused by ESBL-producing E. coli.

Keywords

Acknowledgement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

  1. Zorc JJ, Kiddoo DA, Shaw KN. Diagnosis and management of pediatric urinary tract infections. Clin Microbiol Rev 2005;18:417-22. https://doi.org/10.1128/CMR.18.2.417-422.2005
  2. Briongos-Figuero LS, Gomez-Traveso T, Bachiller-Luque P, Dominguez-Gil Gonzalez M, Gomez-Nieto A, Palacios-Martin T, et al. Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing enterobacteria. Int J Clin Pract 2012;66:891-6. https://doi.org/10.1111/j.1742-1241.2012.02991.x
  3. Jean SS, Coombs G, Ling T, Balaji V, Rodrigues C, Mikamo H, et al. Epidemiology and antimicrobial susceptibility profiles of pathogens causing urinary tract infections in the Asia-Pacific region: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2010-2013. Int J Antimicrob Agents 2016;47:328-34. https://doi.org/10.1016/j.ijantimicag.2016.01.008
  4. Megged O. Extended-spectrum β-lactamase-producing bacteria causing community-acquired urinary tract infections in children. Pediatr Nephrol 2014;29:1583-7. https://doi.org/10.1007/s00467-014-2810-y
  5. Fan NC, Chen HH, Chen CL, Ou LS, Lin TY, Tsai MH, et al. Rise of community-onset urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli in children. J Microbiol Immunol Infect 2014;47:399-405. https://doi.org/10.1016/j.jmii.2013.05.006
  6. Oteo J, Perez-Vazquez M, Campos J. Extended-spectrum (beta)-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis 2010;23:320-6. https://doi.org/10.1097/QCO.0b013e3283398dc1
  7. Wong-Beringer A, Hindler J, Loeloff M, Queenan AM, Lee N, Pegues DA, et al. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin Infect Dis 2002;34:135-46. https://doi.org/10.1086/324742
  8. Tinelli M, Cataldo MA, Mantengoli E, Cadeddu C, Cunietti E, Luzzaro F, et al. Epidemiology and genetic characteristics of extended-spectrum β-lactamase-producing Gram-negative bacteria causing urinary tract infections in long-term care facilities. J Antimicrob Chemother 2012;67:2982-7. https://doi.org/10.1093/jac/dks300
  9. Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother 2011;55:4943-60. https://doi.org/10.1128/AAC.00296-11
  10. Ramphal R, Ambrose PG. Extended-spectrum beta-lactamases and clinical outcomes: current data. Clin Infect Dis 2006;42 Suppl 4:S164-72. https://doi.org/10.1086/500663
  11. Apisarnthanarak A, Hsu LY, Khawcharoenporn T, Mundy LM. Carbapenem-resistant Gram-negative bacteria: how to prioritize infection prevention and control interventions in resource-limited settings? Expert Rev Anti Infect Ther 2013;11:147-57. https://doi.org/10.1586/eri.12.164
  12. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 2006;12:826-36. https://doi.org/10.1111/j.1469-0691.2006.01456.x
  13. Park JY. Should we prescribe carbapenem for treating febrile urinary tract infection caused by extended-spectrum β-lactamase-producing Enterobacteriaceae in children with vesicoureteral reflux? Clin Exp Pediatr 2021.
  14. Doi A, Shimada T, Harada S, Iwata K, Kamiya T. The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae. Int J Infect Dis 2013;17:e159-63.
  15. Sethaphanich N, Santanirand P, Rattanasiri S, Techasaensiri C, Chaisavaneeyakorn S, Apiwattanakul N. Pediatric extended spectrum β-lactamase infection: Community-acquired infection and treatment options. Pediatr Int 2016;58:338-46. https://doi.org/10.1111/ped.12845
  16. Guet-Revillet H, Emirian A, Groh M, Nebbad-Lechani B, Weiss E, Join-Lambert O, et al. Pharmacological study of cefoxitin as an alternative antibiotic therapy to carbapenems in treatment of urinary tract infections due to extended-spectrum-β-lactamase-producing Escherichia coli. Antimicrob Agents Chemother 2014;58:4899-901. https://doi.org/10.1128/AAC.02509-14
  17. Peco-Antic A, Paripovic D, Buljugic S, Spasojevic-Dimitrijeva B, Cvetkovic M, Laban-Nestorovic S, et al. In vivo susceptibility of ESBL producing Escherichia coli to ceftriaxone in children with acute pyelonephritis. Srp Arh Celok Lek 2012;140:321-5. https://doi.org/10.2298/SARH1206321P
  18. Gentry LO. Cephalosporins in urinary tract infection. Drugs 1987; 34 Suppl 2:154-63. https://doi.org/10.2165/00003495-198700342-00012
  19. Vinks AA, Derendorf H, Mouton JW. Fundamentals of antimicrobial pharmacokinetics and pharmacodynamics. Springer, New York: 2014:137-46.
  20. Tratselas A, Iosifidis E, Ioannidou M, Saoulidis S, Kollios K, Antachopoulos C, et al. Outcome of urinary tract infections caused by extended spectrum β-lactamase-producing Enterobacteriaceae in children. Pediatr Infect Dis J 2011;30:707-10. https://doi.org/10.1097/INF.0b013e31820d7ec4
  21. Lee B, Kang SY, Kang HM, Yang NR, Kang HG, Ha IS, et al. Outcome of Antimicrobial Therapy of Pediatric Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae. Infect Chemother 2013;45:415-21. https://doi.org/10.3947/ic.2013.45.4.415
  22. Han SB, Lee SC, Lee SY, Jeong DC, Kang JH. Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae. BMC Infect Dis 2015;15:414. https://doi.org/10.1186/s12879-015-1153-z
  23. Hyun HS, Kim JH, Cho MH, Park E, Ha IS, Cheong HI, et al. Low relapse rate of urinary tract infections from extended-spectrum beta-lactamase-producing bacteria in young children. Pediatr Nephrol 2019;34:2399-407. https://doi.org/10.1007/s00467-019-04298-4
  24. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; 24th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2014.
  25. Rupp ME, Fey PD. Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs 2003;63:353-65. https://doi.org/10.2165/00003495-200363040-00002
  26. Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother 2012;67:2793-803. https://doi.org/10.1093/jac/dks301
  27. Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011;17:1791-8. https://doi.org/10.3201/eid1710.110655
  28. Pitout JD, Laupland KB. Extended-spectrum beta-lactamaseproducing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008;8:159-66. https://doi.org/10.1016/S1473-3099(08)70041-0
  29. Roberts KB. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. Pediatrics 2011;128:595-610. https://doi.org/10.1542/peds.2011-2469
  30. Helm RE. Accepted but Unacceptable: Peripheral IV Catheter Failure: 2019 Follow-up. J Infus Nurs 2019;42:149-50. https://doi.org/10.1097/NAN.0000000000000324
  31. Ullman AJ, Marsh N, Mihala G, Cooke M, Rickard CM. Complications of Central Venous Access Devices: A Systematic Review. Pediatrics 2015;136:e1331-44. https://doi.org/10.1542/peds.2015-1507
  32. Tamma PD, Rodriguez-Bano J. The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections. Clin Infect Dis 2017;64:972-80. https://doi.org/10.1093/cid/cix034
  33. Pilmis B, Parize P, Zahar JR, Lortholary O. Alternatives to carbapenems for infections caused by ESBL-producing Enterobacteriaceae. Eur J Clin Microbiol Infect Dis 2014;33:1263-5. https://doi.org/10.1007/s10096-014-2094-y
  34. Sharara SL, Amoah J, Pana ZD, Simner PJ, Cosgrove SE, Tamma PD. Is Piperacillin-Tazobactam Effective for the Treatment of Pyelonephritis Caused by Extended-Spectrum β-Lactamase-Producing Organisms? Clin Infect Dis 2020;71:e331-e7. https://doi.org/10.1093/cid/ciz1205
  35. Son SK, Lee NR, Ko JH, Choi JK, Moon SY, Joo EJ, et al. Clinical effectiveness of carbapenems versus alternative antibiotics for treating ESBL-producing Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2018;73:2631-42. https://doi.org/10.1093/jac/dky168